| CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies (NCT04156256) | iCell Gene Therapeutics | 2018-03-01 |
| Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations (NCT03381781) | Li Junmin | 2018-03-01 |
| A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML. (NCT03507842) | Asan Medical Center | 2018-03-01 |
| Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML) (NCT03564288) | Oscotec Inc. | 2018-02-23 |
| HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant (NCT03326921) | Fred Hutchinson Cancer Center | 2018-02-23 |
| Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML (NCT03306264) | Astex Pharmaceuticals, Inc. | 2018-02-15 |
| Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy (NCT03422731) | City of Hope Medical Center | 2018-02-15 |
| Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia. (NCT03379727) | Novartis Pharmaceuticals | 2018-02-13 |
| Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia (NCT03041688) | National Cancer Institute (NCI) | 2018-02-08 |
| Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT03092674) | National Cancer Institute (NCI) | 2018-02-02 |
| Nalbuphine Versus Morphine for Mucositis Pain in Pediatric Cancer Patients (NCT03825887) | Children's Cancer Hospital Egypt 57357 | 2018-02-01 |
| Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy (NCT03395873) | Milton S. Hershey Medical Center | 2018-01-29 |
| Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome (NCT03404193) | M.D. Anderson Cancer Center | 2018-01-18 |
| Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome (NCT03383575) | M.D. Anderson Cancer Center | 2018-01-17 |
| A Study of LAM-003 in Patients With Acute Myeloid Leukemia (NCT03426605) | OrphAI Therapeutics | 2018-01-16 |
| Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML) (NCT03154827) | BioLineRx, Ltd. | 2018-01-08 |
| PET/CT and Bacterial/Fungal PCR in High Risk Febrile Neutropenia (NCT03429387) | Peter MacCallum Cancer Centre, Australia | 2018-01-08 |
| A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia (NCT03451084) | ASLAN Pharmaceuticals | 2018-01-05 |
| Microbiota Changes in Acute Myeloid Leukemia Patients Undergoing Intensive Chemotherapy (NCT03728699) | Masonic Cancer Center, University of Minnesota | 2018-01-02 |
| Observational Study of Spatio-Temporal Patterns of New Cases of Acute Myeloid Leukemia (NCT03433521) | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 2018-01-01 |
| Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab (NCT03286114) | University of Michigan Rogel Cancer Center | 2017-12-21 |
| Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia (NCT03318016) | University of Colorado, Denver | 2017-12-15 |
| Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer (NCT03333486) | Roswell Park Cancer Institute | 2017-12-07 |
| Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer (NCT02999854) | Kiadis Pharma | 2017-11-29 |
| Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and Neutropenia (NCT03333005) | Basilea Pharmaceutica | 2017-11-27 |
| Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML) (NCT03303339) | Cardiff Oncology | 2017-11-17 |
| Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy Donors (NCT03233074) | Centre Hospitalier Universitaire de Saint Etienne | 2017-11-17 |
| Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia (NCT02770820) | Fred Hutchinson Cancer Center | 2017-11-06 |
| Ruxolitinib + Allogeneic Stem Cell Transplantation in AML (NCT03286530) | Massachusetts General Hospital | 2017-11-03 |
| Venetoclax Registry (NCT03662724) | Hannover Medical School | 2017-11-01 |
| Ascorbic Acid Levels in MDS, AML, and CMML Patients (NCT03526666) | Van Andel Research Institute | 2017-11-01 |
| MG4101 for Refractory or Relapsed AML (NCT03349502) | Seoul National University Hospital | 2017-11-01 |
| A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy (NCT03310918) | Massachusetts General Hospital | 2017-10-31 |
| Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies (NCT03263637) | AstraZeneca | 2017-10-24 |
| 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia (NCT03128034) | Fred Hutchinson Cancer Center | 2017-10-24 |
| Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant (NCT03068819) | Washington University School of Medicine | 2017-10-23 |
| CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) (NCT03896854) | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 2017-10-18 |
| Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers (NCT04484532) | Roswell Park Cancer Institute | 2017-10-17 |
| Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma (NCT03096782) | M.D. Anderson Cancer Center | 2017-10-13 |
| High-Intensity Parent Intervention Program in Improving Learning and School Functioning in Latino Children With Acute Leukemia or Lymphoblastic Lymphoma (NCT03178617) | City of Hope Medical Center | 2017-10-12 |
| Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia. (NCT03311815) | PETHEMA Foundation | 2017-10-06 |
| Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML). (NCT03298984) | Sumitomo Pharma America, Inc. | 2017-09-25 |
| Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant (NCT03267186) | Andrew Rezvani | 2017-09-12 |
| Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation (NCT03246906) | Fred Hutchinson Cancer Center | 2017-09-11 |
| Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia (NCT03197714) | Hospital Universitario 12 de Octubre | 2017-09-07 |
| Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) (NCT03224819) | Amgen | 2017-09-07 |
| Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT (NCT03256071) | The First Affiliated Hospital of Soochow University | 2017-09-01 |
| Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS (NCT02923986) | Bio-Path Holdings, Inc. | 2017-09-01 |
| Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia (NCT03009240) | City of Hope Medical Center | 2017-08-21 |
| A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) (NCT02997202) | Astellas Pharma Global Development, Inc. | 2017-08-16 |
| Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia (NCT03027102) | University Health Network, Toronto | 2017-08-15 |
| Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer (NCT03154190) | Stanford University | 2017-08-08 |
| Quality of Life in Children With Cancer (NCT03190499) | Cumhuriyet University | 2017-08-01 |
| Gluten Free Diet in Diminishing Side Effects Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy (NCT03108911) | Rutgers, The State University of New Jersey | 2017-07-27 |
| Changes in the Gut Microbiota of Patients Undergoing Allogeneic Stem Cell Transplantation (COLLECT) (NCT03148197) | University of Cologne | 2017-07-14 |
| Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia (NCT03063203) | Washington University School of Medicine | 2017-07-14 |
| Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage (NCT03194932) | St. Jude Children's Research Hospital | 2017-07-11 |
| DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess (NCT03356080) | Shanghai Tong Ren Hospital | 2017-07-07 |
| A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old (NCT03257241) | Polish Adult Leukemia Group | 2017-07-03 |
| Study of Intracellular Nucleotide Pools Determination as Biomarker of the Efficacy of the Induction Treatment in Acute Myeloid Leukemia (NCT03234985) | Hospices Civils de Lyon | 2017-07-01 |
| CD38-targeted Chimeric Antigen Receptor T Cell (CART) in Relapesd or Refractory Acute Myeloid Leukemia (NCT04351022) | The First Affiliated Hospital of Soochow University | 2017-07-01 |
| Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML) (NCT04884984) | The First Affiliated Hospital of Soochow University | 2017-07-01 |
| Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients (NCT03381118) | St. Petersburg State Pavlov Medical University | 2017-06-30 |
| SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (NCT03113643) | Dana-Farber Cancer Institute | 2017-06-26 |
| An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia (NCT03151408) | Helsinn Healthcare SA | 2017-06-23 |
| Interest of a Therapeutic Follow-up of the Cytarabine in the Acute Myeloid Leukaemia: Is There Constitutional Biomarkers (NCT03337516) | Assistance Publique Hopitaux De Marseille | 2017-06-21 |
| A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT03164057) | St. Jude Children's Research Hospital | 2017-06-15 |
| Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) (NCT03150004) | Medical College of Wisconsin | 2017-06-14 |
| Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia (NCT03195010) | Fred Hutchinson Cancer Center | 2017-06-09 |
| Safety and Activity of Digoxin With Decitabine in Adult AML and MDS (NCT03113071) | Fox Chase Cancer Center | 2017-06-02 |
| Haplo HCT vs Haplo-cord HCT for Patients With AML (NCT03719534) | The First Affiliated Hospital of Soochow University | 2017-06-01 |
| Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults (NCT03135028) | Gilead Sciences | 2017-05-19 |
| Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms (NCT03072043) | H. Lee Moffitt Cancer Center and Research Institute | 2017-05-18 |
| QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML (NCT03050216) | Masonic Cancer Center, University of Minnesota | 2017-05-16 |
| UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep (NCT02722668) | Masonic Cancer Center, University of Minnesota | 2017-05-15 |
| Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes (NCT03121014) | University of Illinois at Chicago | 2017-04-24 |
| Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients (NCT02856178) | F2G Ltd | 2017-04-20 |
| Study of Regorafenib in Patients With Advanced Myeloid Malignancies (NCT03042689) | Massachusetts General Hospital | 2017-04-17 |
| Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML (NCT02942758) | University Hospital Regensburg | 2017-04-10 |
| CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia (NCT02995655) | Washington University School of Medicine | 2017-04-07 |
| StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies (NCT02765997) | Masonic Cancer Center, University of Minnesota | 2017-04-01 |
| Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia (NCT02809092) | Hospital de Clinicas de Porto Alegre | 2017-04-01 |
| Alternative Splicing and Leukemia Initiating Cells (NCT03156933) | Hospices Civils de Lyon | 2017-04-01 |
| Allogeneic HCT Using Uniform Conditioning Regimen Regardless of Donors (MS, MU, or HF) for AML in Remission (NCT03337568) | Asan Medical Center | 2017-04-01 |
| A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies (NCT03106428) | MedImmune LLC | 2017-03-29 |
| Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy (NCT03499912) | National Taiwan University Hospital | 2017-03-29 |
| Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia (NCT03019939) | M.D. Anderson Cancer Center | 2017-03-28 |
| Study of AMV564 in Patients With AML (NCT03144245) | Amphivena Therapeutics, Inc. | 2017-03-20 |
| STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy (NCT03063944) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2017-03-17 |
| MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia (NCT03008187) | Menarini Group | 2017-03-10 |
| Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation (NCT02981914) | University of Chicago | 2017-03-07 |
| The Oronasal Microbiota in Pediatric Oncology Patients (NCT02949427) | St. Jude Children's Research Hospital | 2017-03-06 |
| The Use of Decitabine as Induction Therapy for Acute Myeloid Leukemia With Complex and/or Monosomal Karyotype (NCT03080766) | The University of Hong Kong | 2017-03-01 |
| Detection of IDH2 Mutations and Monitoring Molecular Residual Disease in Patients With AML (NCT03537560) | Chang Gung Memorial Hospital | 2017-03-01 |
| Safety and Pharmacokinetics of Oral F901318 (Fluconazole and Posaconazole) IN Aml Leukaemia (NCT03036046) | F2G Ltd | 2017-03-01 |
| Beat AML Core Study (NCT02927106) | University of Florida | 2017-02-15 |
| Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation (NCT02782546) | Washington University School of Medicine | 2017-01-30 |
| Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML (NCT02875093) | Polaris Group | 2017-01-20 |
| Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02960646) | M.D. Anderson Cancer Center | 2017-01-18 |
| Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide (NCT03088709) | Loyola University | 2017-01-18 |